title: The impact of recent advances in immunology and cancer therapy on nuclear medicine.
abstract: The explosive expansion of knowledge in immunology in recent decades has already affected the research and practice of nuclear medicine in several ways. New hematopoietic cells have been isolated and their functions discovered, including hematopoietic stem cells and dendritic cells (DCs). Many new humeral factors have been found that have potent effects on cells, including cytokines, growth factors, and specialized proteins. Radiolabeled compounds are needed to follow the pharmacodynamics of the humeral factors and to follow the migration of mobile cells in animals and humans. In this article, only DCs, cytokines, and growth factors used clinically are discussed. DCs are essential for defense against infectious diseases. Autologous DCs cultured for a week and pulsed with tumor antigens have already proved highly immunogenic compared with other methods for activating cytotoxic T cells, and preliminary studies suggest that DCs are more potent for tumor cell killing than monoclonal antibodies. DCs, unfortunately, also play an important role in causing certain human diseases. In allograft transplants, residual donor DCs are responsible for the cellular rejection; if they could be eliminated, rejection could be prevented. These cells are also detrimental in rheumatoid arthritis, other autoimmune diseases, asthma, and chronic obstructive pulmonary disease. Cytokines such as interleukin-2 and such growth factors as granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor, administered to patients with malignancies to alleviate the leukopenia of chemotherapy agents, frequently alter the tissue distribution of radiopharmaceuticals; these alterations may be confused with disease.
authors.affiliation: Department of Nuclear Medicine, The National Institutes of Health, Bethesda, MD 20892-1180, USA.
authors.forename: J G
authors.initials: JG
authors.lastname: McAfee
authors.forename: T J
authors.initials: TJ
authors.lastname: MacVittie
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001853:Bone Marrow / Q000000981:diagnostic imaging; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002465:Cell Movement; D016207:Cytokines / Q000502:physiology; D003713:Dendritic Cells / Q000276:immunology* / Q000502:physiology; D006084:Graft Rejection / Q000276:immunology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007205:Indium Radioisotopes; D007249:Inflammation / Q000276:immunology / Q000503:physiopathology; D008099:Liver / Q000000981:diagnostic imaging; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000276:immunology / Q000628:therapy*; D009942:Organometallic Compounds; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013601:T-Lymphocytes / Q000276:immunology; D014334:Tropolone / Q000031:analogs & derivatives*
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D016207:Cytokines; D007205:Indium Radioisotopes; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C043895:indium tris(tropolonate); D016179:Granulocyte Colony-Stimulating Factor; D014334:Tropolone